title: The emerging role of serum/glucocorticoid-regulated kinases in cancer.
authors.affiliation: a Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center , New York , NY , USA.
authors.forename: Pau
authors.initials: P
authors.lastname: Castel
authors.affiliation: a Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center , New York , NY , USA.|b Department of Pathology , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Scaltriti
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D006801:Humans; D017874:Immediate-Early Proteins / Q000378:metabolism*; D000076222:Mechanistic Target of Rapamycin Complex 1 / Q000378:metabolism; D008954:Models, Biological; D009369:Neoplasms / Q000201:enzymology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D000099184:Serum-Glucocorticoid Regulated Kinases
chemical_list: D017874:Immediate-Early Proteins; D000076222:Mechanistic Target of Rapamycin Complex 1; D019869:Phosphatidylinositol 3-Kinases; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D000099184:Serum-Glucocorticoid Regulated Kinases
keywords: AKT; PI3K inhibitors; PIK3CA; SGK1; TSC2; drug resistance; mTORC1